MedPath
NMPA Approval

Rilertinib Mesylate Tablets

国药准字H20240020

June 11, 2024

Drug Information

甲磺酸瑞厄替尼片

圣瑞沙

片剂

100mg(按C₃₁H₃₇N₇O₂计)

化学药品

June 11, 2024

Company Information

Applicant Company

南京市经济技术开发区惠中路9号

Manufacturing Company

南京市经济技术开发区惠中路9号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

甲磺酸瑞厄替尼片 - NMPA 批准文号 | MedPath